<DOC>
	<DOCNO>NCT02234024</DOCNO>
	<brief_summary>The purpose pilot project see supplemental form dietary gangliosides serve potential treatment rare metabolic condition call ganglioside GM3 synthase deficiency .</brief_summary>
	<brief_title>Oral Supplementation Gangliosides Treat Rare Metabolic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Clinical diagnosis GM3 synthase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>